Adherex Technologies Inc.

Type: Public
On the web: http://www.adherex.com

Working nimbly with a very sticky subject, Adherex Technologies researches and develops cancer treatments. Its lead drug candidate, Exherin, targets a tumor's blood supply and makes those blood vessels weak and leaky by disrupting a key protein. Other drug candidates could help prevent hearing loss in children undergoing certain types of chemotherapy; make cancer cells more vulnerable to anti-cancer drugs; and prevent thrombocytopenia, the loss of blood platelets during chemotherapy. Adherex Technologies' pipeline is strongly based on compounds that disrupt cadherins, proteins that adhere like molecules together in cell adhesion. Southpoint Capital Advisors control more than 42% of the company.

Officers:
Chairman and CEO: William P. (Bill) Peters
President, COO, and Director: Robin J. Norris
CFO: James A. (Jim) Klein Jr.

Competitors:
Embrex
GlaxoSmithKline R & D
OXiGENE

Antidiuretic hormone.

• ADH response test — see antidiuretic hormone.